Asenapine
Saphris
- Dosage form
- Tablet
- Available strengths
- 5 mg, 10 mg
- Drug class
- Atypical antipsychotic
- Common brand
- Saphris
Clinical overview. Asenapine (Saphris) is an atypical antipsychotic taken as a sublingual tablet to treat schizophrenia and manic or mixed episodes of bipolar I disorder in adults. It carries a serious warning for increased mortality in elderly patients with dementia-related psychosis and can cause somnolence, akathisia, weight gain, and metabolic changes. Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe allergic reactions, and QT prolongation, so regular monitoring is recommended.
Indication
Common therapeutic uses
- Asenapine is used to treat schizophrenia in adults.
- Asenapine is used for the acute treatment of manic or mixed episodes associated with bipolar I disorder, either alone or together with lithium or divalproex sodium.
- Patients using asenapine for extended periods should have the ongoing risks and benefits periodically reassessed by their physician.
Pregnancy
Risk assessment and monitoring considerations
- Asenapine should not be used during pregnancy unless clearly necessary, since animal studies showed maternal and fetal toxicity and adequate human data are lacking.
- Babies exposed to asenapine during the third trimester can experience withdrawal or extrapyramidal symptoms after birth, including agitation, tremor, abnormal muscle tone, and feeding or breathing difficulties, which can range from mild and self-limited to severe enough to require intensive care.
Breastfeeding
Infant exposure considerations
- Breastfeeding is not recommended during asenapine treatment, since it is not known whether asenapine passes into human milk, though it has been detected in the milk of nursing animals.
Geriatrics
Dosing and tolerability considerations
- Asenapine should be used with care in elderly patients, since safety and efficacy data in patients 65 years of age or older are limited and this group is more prone to hepatic, renal, cardiovascular, and central nervous system effects.
- Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs have an increased risk of death, mainly from cardiovascular or infectious causes, and asenapine is not approved for this use.
Pediatrics
Use in children and adolescents
- Safety and effectiveness of asenapine have not been established in patients under 18 years of age, and it is not recommended for pediatric use; a pediatric schizophrenia trial failed to meet its primary efficacy objectives.
- Children and adolescents treated with asenapine experienced greater weight gain and a higher rate of new-onset metabolic syndrome than adults.
Dosage & Administration
Practical dosing and administration
- For schizophrenia, the recommended starting and target dose is 5 mg placed under the tongue twice daily, since 10 mg twice daily has not shown added benefit and causes more side effects.
- For bipolar disorder, the recommended starting dose is 5 mg twice daily, which can be increased to 10 mg twice daily based on response and tolerability.
- The sublingual tablet must be allowed to dissolve completely under the tongue and should never be swallowed, crushed, or chewed, and patients should avoid eating or drinking for 10 minutes afterward.
- If other oral medications are taken at the same time, asenapine should be taken last.
- No dosage adjustment is needed for elderly patients, renal impairment, or mild to moderate hepatic impairment, but asenapine is not recommended in severe hepatic impairment.
- If a dose is missed, it should be taken as soon as possible, but a double dose should never be taken to make up for a missed one.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Reported overdose cases have involved agitation, confusion, restlessness (akathisia), abnormal facial or mouth muscle spasms (orofacial dystonia), and sedation.
- Some cases have shown symptomless ECG changes, such as a slowed heart rate, extra heartbeats, or delays in the heart's electrical conduction.
- There is no specific antidote for asenapine overdose.
- Cardiovascular monitoring is recommended to detect possible heart rhythm abnormalities.
- Treatment is supportive, focusing on maintaining an open airway and adequate oxygenation and ventilation.
- Low blood pressure or circulatory collapse may be treated with intravenous fluids or certain blood-pressure-supporting medications, though epinephrine and dopamine should be avoided since they may worsen asenapine-related hypotension.
- Severe extrapyramidal symptoms (abnormal, involuntary muscle movements) may be treated with anticholinergic medication.
Common side effects
Frequently reported tolerability concerns
- Somnolence (sleepiness) may occur.
- Dizziness may occur.
- Akathisia (restlessness) may occur.
- Extrapyramidal symptoms, such as tremor or muscle stiffness, may occur.
- Oral hypoesthesia or numbness of the mouth may occur directly after taking the tablet and usually resolves within an hour.
- Increased appetite may occur.
- Weight gain may occur.
- Constipation may occur.
- Dry mouth may occur.
- Salivary hypersecretion may occur.
- Nausea or vomiting may occur.
- Fatigue may occur.
- Insomnia may occur.
- Headache may occur.
- Irritability may occur.
- Dysgeusia (altered taste) may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Elderly patients with dementia-related psychosis treated with asenapine have an increased risk of death.
- Serious hypersensitivity reactions, including anaphylaxis and angioedema, may occur, sometimes after the very first dose.
- Neuroleptic malignant syndrome, a potentially fatal reaction with high fever, muscle rigidity, and altered mental status, may occur.
- Tardive dyskinesia, a syndrome of potentially irreversible involuntary movements, may develop, especially with long-term use.
- Severe orthostatic hypotension and fainting (syncope) may occur, particularly early in treatment.
- QT interval prolongation may occur, increasing the risk of dangerous heart rhythm disturbances.
- Severe neutropenia and agranulocytosis may occur.
- Venous thromboembolism, including fatal pulmonary embolism, has been reported.
- Seizures may occur, particularly in patients with a history of seizure disorder.
- Severe hyperglycemia and diabetic ketoacidosis may occur, even in patients without a prior diagnosis of diabetes.
- Severe constipation requiring medical intervention may occur.
- Suicidal ideation and behaviour may occur, as with other antipsychotics used for psychotic and bipolar disorders.
- Drug reaction with eosinophilia and systemic symptoms has been reported with similar antipsychotics in this class.
- Seek urgent medical attention for high fever with muscle stiffness, difficulty breathing or swallowing, swelling of the face or throat, fainting, or a very fast or irregular heartbeat.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension, given the risk of orthostatic hypotension.
- Use with caution in patients with diabetes or risk factors for diabetes, monitoring blood glucose regularly.
- Use with caution in patients with a pre-existing low white blood cell count or history of drug-induced neutropenia, with frequent blood count monitoring during the first months of therapy.
- Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.
- Use with caution in patients at risk of aspiration pneumonia, since esophageal dysmotility and dysphagia have been associated with antipsychotic use.
- Use with caution in patients with a history of substance abuse, since dependence and abuse potential have not been fully studied.
- Use with caution in patients at risk for falls, since somnolence, dizziness, and extrapyramidal symptoms can increase fall risk.
- Use with caution in patients with a history of sleep apnea, since atypical antipsychotics have been associated with sleep apnea, with or without weight gain.
- Use with caution when prescribing to patients who will be exposed to conditions that raise body temperature, such as strenuous exercise, heat exposure, or dehydration.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to asenapine or to any ingredient in the formulation.
Drug interactions
Clinically relevant combinations
- Fluvoxamine, a strong CYP1A2 inhibitor, can increase asenapine blood levels and should be co-administered with caution.
- Paroxetine blood levels can roughly double when combined with asenapine, since asenapine weakly inhibits the CYP2D6 enzyme that breaks paroxetine down.
- Other centrally acting drugs and alcohol can add to asenapine's sedative effects and should be used cautiously together.
- Antihypertensive medications may have their blood-pressure-lowering effects enhanced by asenapine due to its alpha-1 adrenergic blocking activity.
- Drugs that prolong the QT interval, such as Class 1A antiarrhythmics like quinidine, Class 3 antiarrhythmics like amiodarone or sotalol, other antipsychotics like ziprasidone, and antibiotics like moxifloxacin, should be avoided in combination with asenapine.
Food interactions
Meal-related administration
- Eating or drinking should be avoided for 10 minutes after taking asenapine, since food consumed shortly before or after dosing can reduce absorption of the sublingual tablet.
Time of administration
Practical scheduling
- Asenapine is typically taken twice daily; if taking other oral medications at the same time, take asenapine last, and wait 10 minutes before eating or drinking.
Storage
Product handling
- Store asenapine sublingual tablets at room temperature, keeping them in the sealed blister until immediately before use.
Patient take-away
Key counselling points for a quick closing summary
- Asenapine is placed under the tongue and must dissolve completely rather than being swallowed, chewed, or crushed, with no food or drink for 10 minutes afterward.
- Report any fever with muscle stiffness, uncontrolled movements, fainting, signs of high blood sugar, or thoughts of self-harm to your doctor right away.
- Because asenapine can cause drowsiness and dizziness, avoid driving or operating machinery until you know how it affects you.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.